HENDERSON, Nev., June 17, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay…

Read the full release →

News provided by PR Newswire.